



Bolivia (Plurinational State of)

Region of the Americas




I. Epidemiological profile

Population (UN)	2016	%	Parasites and vectors
High transmission (> 1 case per 1000 population)	272,000	2	Plasmodium species: <i>P. falciparum</i> (0%), <i>P. vivax</i> (100%)
Low transmission (0-1 cases per 1000 population)	4,670,000	43	Major anopheles species: <i>An. darlingi</i> , <i>An. pseudopunctipennis</i>
Malaria-free (0 cases)	5,950,000	55	Reported confirmed cases (health facility): 5,542 Estimated cases: 7,000 [2,400-14,030]
Total	10,890,000		Confirmed cases at community level: - Reported deaths: 0 Estimated deaths: ≤ 10


II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	Yes	2008	First-line treatment of unconfirmed malaria	-	-					
	ITNs/ LLINs distributed to all age groups	Yes	-	First-line treatment of <i>P. falciparum</i>	AL	2001					
IRS	IRS is recommended	Yes	1959	Treatment failure of <i>P. falciparum</i>	-	-					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	AS	2001					
Larval control	Use of larval control recommended	No	-	Treatment of <i>P. vivax</i>	CQ+PQ(7d)	2001					
IPT	IPT used to prevent malaria during pregnancy	N/A	-	Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.25 mg/Kg (14 days)					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	-	Type of RDT used		-					
	Malaria diagnosis is free of charge in the public sector	Yes	1996								
Treatment	ACT is free of charge for all ages in public sector	Yes	-	Therapeutic efficacy tests (clinical and parasitological failure, %)							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Is banned	-	Medicine	Year(s)	Min	Median	Max	Follow-up	No. of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	No	-	CQ	2011-2011	10.4	10.4	10.4	28 days	1	<i>P. vivax</i>
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	-	Insecticide resistance tests (mosquito mortality, %)							
	G6PD test is a requirement before treatment with primaquine	No	-	Insecticide class	Years	Min	Mean	Max	No. of sites	Species	
	Directly observed treatment with primaquine is undertaken	Yes	-	Organochlorines	2011-2015	1	1	1	4	<i>An. darlingi</i>	
	System for monitoring adverse reactions to antimalarials exists	Yes	-	Carbamates	2011-2015	0.4	0.9	1	5	<i>An. darlingi</i>	
Surveillance	ACD for case investigation (reactive)	Yes	-	Pyrethroids	2011-2015	0.5	0.9	1	6	<i>An. darlingi</i>	
	ACD of febrile cases at community level (pro-active)	Yes	-								
	Mass screening is undertaken	Yes	1998								
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	-								
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-								
	Foci and case investigation undertaken	-	-								
Case reporting from private sector is mandatory	No	-									


III. Financing




Government expenditure by intervention in 2016




IV. Coverage




Cases tested and treated in public sector




V. Impact



Test positivity



Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths

